These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21040668)

  • 61. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.
    Liu Q; Xuan L; Liu H; Huang F; Zhou H; Fan Z; Zhao K; Wu M; Xu L; Zhai X; Zhang F; Liu C; Sun J; Huang X
    Am J Hematol; 2013 Jul; 88(7):550-5. PubMed ID: 23564232
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Complete resolution of posttransplant lymphoproliferative disorder (diffuse large B-cell lymphoma) with reduction of immunosuppressive therapy.
    Ryu HJ; Hahn JS; Kim YS; Park K; Yang WI; Lee JD
    Yonsei Med J; 2004 Jun; 45(3):527-32. PubMed ID: 15227742
    [TBL] [Abstract][Full Text] [Related]  

  • 63. EBV-positive extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in the posttransplant setting: a distinct type of posttransplant lymphoproliferative disorder?
    Gibson SE; Swerdlow SH; Craig FE; Surti U; Cook JR; Nalesnik MA; Lowe C; Wood KM; Bacon CM
    Am J Surg Pathol; 2011 Jun; 35(6):807-15. PubMed ID: 21552113
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
    Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
    Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
    Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Epstein-Barr virus gastric ulcer associated with ruxolitinib.
    Kusano Y; Terui Y; Ueda K; Hatake K
    Ann Hematol; 2016 Oct; 95(10):1741-2. PubMed ID: 27411541
    [No Abstract]   [Full Text] [Related]  

  • 68. An unusual presentation of cerebellar lymphoma.
    Harley B; Shivapathasundram G; Astradsson A; Muthurajah V; Wickremesekera A
    J Clin Neurosci; 2018 Nov; 57():177-180. PubMed ID: 30146400
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation.
    Cibeira MT; Lopez-Guillermo A; Colomer D; Ricart MJ; Alcaraz A; Martinez A; Campo E; Montserrat E
    Ann Hematol; 2003 Feb; 82(2):131-135. PubMed ID: 12601496
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Successful Treatment of Posttransplant EBV-Associated Lymphoma and Plasmacytoma Solely Localized to the CNS.
    Hansen PB; Nielsen SL
    Case Rep Hematol; 2012; 2012():497614. PubMed ID: 22937330
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hepatitis C virus infection and rituximab therapy after renal transplantation.
    Fabrizi F; Martin P; Elli A; Montagnino G; Banfi G; Passerini P; Campise MR; Tarantino A; Ponticelli C
    Int J Artif Organs; 2007 May; 30(5):445-9. PubMed ID: 17551909
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Violaceous Nodule in a Lung-transplant Patient.
    Milford E; Winslow C; Danhof R
    Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617611
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Unusual primary central nervous system lymphoma location involving the fourth ventricle and hypothalamus.
    Cellina M; Fetoni V; Baron P; Orsi M; Oliva G
    Neuroradiol J; 2015 Apr; 28(2):120-5. PubMed ID: 25923685
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases.
    Garcia VD; Bonamigo-Filho JS; Neumann J; Fogliatto L; Gaiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Santos AF; Roithmann S
    Transplant Proc; 2002 Nov; 34(7):2993-5. PubMed ID: 12431680
    [No Abstract]   [Full Text] [Related]  

  • 75. Survival in patients with glioblastoma receiving valganciclovir.
    Söderberg-Nauclér C; Rahbar A; Stragliotto G
    N Engl J Med; 2013 Sep; 369(10):985-6. PubMed ID: 24004141
    [No Abstract]   [Full Text] [Related]  

  • 76. Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma.
    Chan TSY; Khong PL; Au-Yeung R; Kwong YL; Tse E
    Ann Hematol; 2019 Sep; 98(9):2227-2230. PubMed ID: 31346688
    [No Abstract]   [Full Text] [Related]  

  • 77. Posttransplant lymphoproliferative disorders in kidney transplant patients: central nervous system involvement.
    Einollahi B
    Iran J Kidney Dis; 2012 Sep; 6(5):330-2. PubMed ID: 22976255
    [No Abstract]   [Full Text] [Related]  

  • 78. [Questionable effect of antiviral therapy in malignant brain tumors].
    Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
    Lakartidningen; 2014 Apr 29-May 13; 111(18-19):809. PubMed ID: 24855749
    [No Abstract]   [Full Text] [Related]  

  • 79. Is rituximab safe to use in kidney transplant patients?
    Jordan SC; Glotz D
    Am J Transplant; 2010 Jan; 10(1):8-9. PubMed ID: 19958329
    [No Abstract]   [Full Text] [Related]  

  • 80. Rituximab may not lead to increased infection rates in transplant recipients.
    Drage M; Hadjianastassiou V; Dorling A; Mamode N
    Am J Transplant; 2010 Dec; 10(12):2723-4. PubMed ID: 21114650
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.